Topoisomerase sequences of coagulase-negative staphylococcal isolates resistant to ciprofloxacin or trovafloxacin

被引:23
作者
Dubin, DT
Fitzgibbon, JE
Nahvi, MD
John, JF
机构
[1] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Mol Genet & Microbiol, Piscataway, NJ 08854 USA
[2] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Div Allergy Immunol & Infect Dis, Piscataway, NJ 08854 USA
[3] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Med, Piscataway, NJ 08854 USA
关键词
D O I
10.1128/AAC.43.7.1631
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Coagulase-negative staphylococcal isolates (n = 188) were screened for susceptibility to oxacillin, ciprofloxacin, and trovafloxacin, a new fluoroquinolone. At an oxacillin concentration of greater than or equal to 4 mu g/ml, 43% were methicillin resistant; of these, 70% were ciprofloxacin resistant (MIC, greater than or equal to 4 mu g/ml). Of the methicillin-resistant, ciprofloxacin-resistant isolates, 46% were susceptible to less than or equal to 2 mu g of trovafloxacin per mi and 32% were susceptible to less than or equal to 1 mu g of trovafloxacin per mi. Sixteen isolates, including twelve that expressed fluoroquinolone resistance, were chosen for detailed analysis. Identification of species by rRNA sequencing revealed a preponderance of Staphylococcus haemolyticus and S, hominis among fluoroquinolone-resistant strains. Segments of genes (gyrA and grlA) encoding DNA gyrase and DNA topoisomerase IV were sequenced. Considerable interspecies variation was noted, mainly involving noncoding nucleotide changes. Intraspecies variation consisted of coding changes associated with fluoroquinolone resistance. As for S, aureus, ciprofloxacin resistance (MIC, greater than or equal to 8 mu g/ml) and increased trovafloxacin MICs (0.25 to 2 mu g/ml) could be conferred by the combined presence of single mutations in each gyrA and grlA gene. Trovafloxacin MICs of greater than or equal to 8 mu g/ml also occurred, but these required an additional mutation in grlA.
引用
收藏
页码:1631 / 1637
页数:7
相关论文
共 43 条
[11]   ANALYSIS OF GYRA AND GRLA MUTATIONS IN STEPWISE-SELECTED CIPROFLOXACIN-RESISTANT MUTANTS OF STAPHYLOCOCCUS-AUREUS [J].
FERRERO, L ;
CAMERON, B ;
CROUZET, J .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (07) :1554-1558
[12]   Topoisomerase mutations in trovafloxacin-resistant Staphylococcus aureus [J].
Fitzgibbon, JE ;
John, JF ;
Delucia, JL ;
Dubin, DT .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (08) :2122-2124
[13]   In vitro activity of trovafloxacin against ciprofloxacin-susceptible and -resistant clinical bacterial isolates and assessment of the trovafloxacin disk test [J].
Fuchs, PC ;
Barry, AL ;
Brown, SD .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1999, 33 (01) :33-38
[14]   Antibacterial activity of gatifloxacin (AM-1155, CG5501, BMS-206584), a newly developed fluoroquinolone, against sequentially acquired quinolone-resistant mutants and the norA transformant of Staphylococcus aureus [J].
Fukuda, H ;
Hori, S ;
Hiramatsu, K .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (08) :1917-1922
[15]   Rapid identification by specific PCR of coagulase-negative staphylococcal species important in hospital infection [J].
Gribaldo, S ;
Cookson, B ;
Saunders, N ;
Marples, R ;
Stanley, J .
JOURNAL OF MEDICAL MICROBIOLOGY, 1997, 46 (01) :45-53
[16]   Correlation between quinolone susceptibility patterns and sequences in the A and B subunits of DNA gyrase in mycobacteria [J].
Guillemin, I ;
Jarlier, V ;
Cambau, E .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (08) :2084-2088
[17]   NOVEL QUINOLONE RESISTANCE MUTATIONS OF THE ESCHERICHIA-COLI DNA GYRASE A-PROTEIN - ENZYMATIC ANALYSIS OF THE MUTANT PROTEINS [J].
HALLETT, P ;
MAXWELL, A .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1991, 35 (02) :335-340
[18]   Identification of DNA gyrase a mutations in ciprofloxacin-resistant isolates of Salmonella typhimurium from men and cattle in Germany [J].
Heisig, P ;
Kratz, B ;
Halle, E ;
Graser, Y ;
Altwegg, M ;
Rabsch, W ;
Faber, JP .
MICROBIAL DRUG RESISTANCE-MECHANISMS EPIDEMIOLOGY AND DISEASE, 1995, 1 (03) :211-218
[19]   Bacterial topoisomerases, anti-topoisomerases, and anti-topoisomerase resistance [J].
Hooper, DC .
CLINICAL INFECTIOUS DISEASES, 1998, 27 :S54-S63